Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...2728293031323334353637...123124»
  • ||||||||||  Review, Journal, Metastases:  Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review. (Pubmed Central) -  Aug 3, 2023   
    This narrative review found that atezolizumab plus bevacizumab is regarded as the primary standard of care for advanced HCC in the first-line setting. These findings from integrating the recommendations from scientific societies' guidelines for managing advanced HCC along with new data from cross-trial comparisons may aid clinicians in decision-making and guide them through a rapidly evolving and complex treatment landscape.
  • ||||||||||  Avastin (bevacizumab) / Roche, IBI-323 / Innovent Biologics, Alecensa (alectinib) / Roche
    Biomarker, Trial completion date, Trial primary completion date:  Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC (clinicaltrials.gov) -  Aug 1, 2023   
    P2,  N=80, Not yet recruiting, 
    The combination of HAIC, lenvatinib, tislelizumab, and TAE was feasible in HCC patients with PVTT and high tumor burden, with tolerable safety. Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), simridarlimab (IBI-322) / Innovent Biologics
    Biomarker, Enrollment change, Trial completion date, Trial primary completion date:  Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) -  Aug 1, 2023   
    P2,  N=83, Not yet recruiting, 
    Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 N=40 --> 83 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion, Trial completion date, Trial primary completion date:  Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma (clinicaltrials.gov) -  Aug 1, 2023   
    P=N/A,  N=30, Completed, 
    N=40 --> 83 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Oct 2024 Recruiting --> Completed | Trial completion date: Oct 2022 --> Mar 2023 | Trial primary completion date: Oct 2022 --> Mar 2023
  • ||||||||||  EG-007 / Evergreen Therap
    Trial completion date, Trial primary completion date:  Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem (clinicaltrials.gov) -  Jul 31, 2023   
    P2,  N=28, Not yet recruiting, 
    Finally, biosimilar-AFL may improve the efficiency of LEN, EVR, and SOR in reducing the VEGF effect on endothelial cells. Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Mar 2024 --> Jul 2024
  • ||||||||||  Torisel (temsirolimus) / Pfizer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology. (Pubmed Central) -  Jul 30, 2023   
    We also provide a user-friendly web portal to help serve the biomedical research community. Our study is a rich resource for investigation of liver cancer biology and pharmacological dependencies and may help enable functional precision medicine.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    A Rare Case of Sinusoidal Obstruction Syndrome After Pembrolizumab Therapy (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_4399;    
    The mortality of untreated severe SOS is > 80%. Figure: Figure 1: Liver biopsy demonstrating (A) sinusoidal dilation with marked sinusoidal congestion along with adjacent hepatocyte plate and hepatocyte atrophy and (B) inflammatory cells and debris within the hepatic veins and surrounding fibrosis.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Histological findings of thyroid cancer after lenvatinib therapy. (Pubmed Central) -  Jul 28, 2023   
    Lenvatinib therapy probably induces relatively specific ischaemic changes in thyroid cancer cells. Moreover, inflammatory cell infiltration and decreased MVD occur to varying degrees in non-cancerous thyroid tissue and may be related to hypothyroidism, a side effect of lenvatinib.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Precision oncology in advanced thyroid carcinomas: Impact of molecular tests on patients' outcomes () -  Jul 27, 2023 - Abstract #ESMO2023ESMO_3655;    
    In Italy, patients (pts) with 131I-refractory differentiated/poorly differentiated TC (DTC/PDTC) can receive lenvatinib/cabozantinib in 1st/2nd line (L), respectively...The majority of pts received NT in MAPs. PD-L1 test/NGS panels including TMB may further expand the therapeutic options.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis () -  Jul 27, 2023 - Abstract #ESMO2023ESMO_3536;    
    Methods Thirty-three patients with metastatic solid tumors (renal, hepatocellular and thyroid cancer) treated with lenvatinib (19 (58%) male), age 61,7 +/- 8,9 years), were examined...Conclusions AH is early adverse reaction of TKI-treatment and besides ABPM could be important component for early diagnosis of such type of secondary AH. Masked isolated nocturnal hypertension was more common phenotype among initially normotensive patients with TKI intake.
  • ||||||||||  Systemic therapy for KIT/PDGFRA wild-type GIST () -  Jul 27, 2023 - Abstract #ESMO2023ESMO_3420;    
    Conclusions This retrospective series of KPWT GIST is one of the largest with this rare disease. Although there was no response to first line TKI imatinib, some long responders are reported with anti-angiogenic TKI and warrant additional investigation through prospective trials to validate those results.
  • ||||||||||  Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus () -  Jul 27, 2023 - Abstract #ESMO2023ESMO_2555;    
    And no significant differences in the incidence of AEs between the two groups, except for those related to Sintilimab. Conclusions TACE combined with lenvatinib and sintilimab improved survival outcomes without increasing the unpredictable safety profile compared with TACE combined with lenvatinib for HCC with PVTT.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Associations of online search trends and prescription trends for hepatocellular carcinoma drugs () -  Jul 27, 2023 - Abstract #ESMO2023ESMO_2550;    
    Sorafenib use, however, steeply declined by 17.56-fold(Q1 2019-Q4 2022)...Lenvatinib (r=0.90), cabozantinib (r=0.67), and pembrolizumab (r=0.54) had the highest correlations between online searches and prescriptions, and all three showed increasing trends...Conclusions Over a 5-year period, the utilization of HCC drugs in the US increased and prescription patterns changed due to positive trial results and guideline changes. There was a positive correlation between online searches and prescription trends for HCC drugs.
  • ||||||||||  Tevimbra (tislelizumab) / BeiGene
    Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma () -  Jul 27, 2023 - Abstract #ESMO2023ESMO_2546;    
    Methods Between April, 2021, and March, 2023, we retrospectively analyzed clinical data of patients with uHCC who underwent tislelizumab ,TKIs(Lenvatinib, Donafenib) and FOLFOX4-HAIC...All TRAES were tolerable and manageable. Conclusions Tislelizumab combined with TKIs and FOLFOX4-HAIC showed high conversion rate and acceptable toxicity in the treatment of uHCC, suggesting that this combination could be considered as a new conversion strategy in this population.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC) () -  Jul 27, 2023 - Abstract #ESMO2023ESMO_2544;    
    Background Cabo is approved in aHCC patients (pts) with prior sorafenib use...The most common regimens were lenvatinib (61.8%) in the TKI cohort, atezolizumab + bevacizumab (91.9%) in the IO+non-IO cohort, and nivolumab (73.3%) in the IO mono or IO+IO cohort...Conclusions This study demonstrates the real-world effectiveness and safety of cabo in 2L aHCC following prior TKIs or IO-based regimens. TNTD, a proxy of progression-free survival, was consistent across different 1L therapies.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma () -  Jul 27, 2023 - Abstract #ESMO2023ESMO_2517;    
    All the data available about second-line therapies derive from trials conducted in patients who progressed to first-line sorafenib therapy...Conclusions Approximately half of patients receiving first-line L or AB access second-line treatment. Our data suggest that in patients progressed to AB, the systemic therapy able to achieve the longest survival is L, while in patients progressed to L, the systemic therapy able to achieve the longest survival is immunotherapy.
  • ||||||||||  Kaitanni (cadonilimab) / Akesobio, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial () -  Jul 27, 2023 - Abstract #ESMO2023ESMO_2492;    
    P1/2
    3 TRAEs occured in 66.1% of patients, and serious AEs were reported in 39.0% of cases.All AEs were expected and manageable.All the deaths were related to disease progression and not related to Cadonilimab. Table: 947P Summary of Efficacy analysis and tumor response by investigator review per RECIST v1.1 Conclusions This novel combination therapy of PD-1/CTLA4 bispecific monoclonal antibody and lenvatinib showed promising efficacy and manageable toxicity that could provide an option of treatment in first-line setting of aHCC.